Spectrum Therapeutics Australia (Spectrum), the medical division of Canopy 
Growth Corporation Australia (Canopy Growth), is pleased to announce that the 
Therapeutic Goods Administration (TGA) has approved the registration of its 
Storz & Bickel GmbH & Co. KG (Storz & Bickel) medical standard vapourisers and 
an update on local operations. 

Logo - https://mma.prnewswire.com/media/968874/SpectrumTherapeuticsLogo_Logo.jpg
 
With a 22-year track record of breakthrough innovations, Storz & Bickel is 
widely recognised as the global leader in medically approved vapouriser design 
and manufacturing, most notably the Volcano(R) Medic and the Mighty(R) Medic. 
Storz & Bickel has spent the last two decades developing an automated and 
internationally certified factory, achieving ISO 13485(1) certification in 2009.
 
"Medicinal cannabis is not a one-size-fits-all approach," said Ben Quirin, 
Asia-Pacific Managing Director, Canopy Growth, "so having a registered device 
available for patients is crucial to ensuring a range of products are available 
locally that meets the diverse needs of patients and can be administered safely 
with the support of their medical professional."

Canopy, parent company of Storz & Bickel, launched ( 
https://www.medianet.com.au/releases/159212/ ) its Spectrum Therapeutic 
Asia-Pacific Headquarters last year and is currently importing products from 
Canada, which have been tested to comply with TG093 standards, while the 
facility, located in Victoria, is retrofitted and licensed to meet Australian 
regulatory standards.

"Patient numbers are growing in Australia, we are seeing this in the SAS 
approval numbers. While we are currently importing our products from Canada, 
our first priority has always been to deliver locally produced medicinal 
cannabis products for patients," says Quirin. 

"We have secured the permits required to start construction, with the 
expectation of completion by first quarter 2020. Our completed facility will 
produce approximately 15,500 kg of dry flower per year which we will use to 
develop standardised and GMP-certified dried flower, oil and Softgel capsules."
 
Here's to Future Growth.

(1) An ISO 13485 certification means that the Storz & Bickel's facilities have 
been scrutinised by external auditors and found to be compliant with all 
requirements needed to produce medical devices.

Contact:

Canopy Growth Australia
Renee Shingles
Media Relations
renee.shingles@canopygrowth.com
+61 402 759 238

About Canopy Growth Corporation
Canopy Growth (TSX: WEED, NYSE: CGC) is a world-leading diversified cannabis, 
hemp and cannabis device company, offering distinct brands and curated cannabis 
varieties in dried, oil and Softgel capsule forms, as well as medical devices 
through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product 
and process innovation to market execution, Canopy Growth is driven by a 
passion for leadership and a commitment to building a world-class cannabis 
company one product, site and country at a time. The Company has operations in 
over a dozen countries across five continents. The Company's medical division, 
Spectrum Therapeutics, is proudly dedicated to educating healthcare 
practitioners, conducting robust clinical research, and furthering the public's 
understanding of cannabis, and has devoted millions of dollars toward cutting 
edge, commercialisable research and IP development. Spectrum Therapeutics sells 
a range of full-spectrum products using its colour-coded classification 
Spectrum system as well as single cannabinoid Dronabinol under the brand 
Bionorica Ethics. The Company operates retail stores across Canada under its 
award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognised 
cannabis brand which has built a large and loyal following by focusing on 
quality products and meaningful customer relationships. From our historic 
public listing on the Toronto Stock Exchange and New York Stock Exchange to our 
continued international expansion, pride in advancing shareholder value through 
leadership is engrained in all we do at Canopy Growth. Canopy Growth has 
established partnerships with leading sector names including cannabis icons 
Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, 
and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy 
Growth operates eleven licensed cannabis production sites with over 4.7 million 
square feet of production capacity, including over one million square feet of 
GMP certified production space. For more information visit www.canopygrowth.com

About Spectrum Therapeutics
Spectrum Therapeutics, the medical division of Canopy Growth Corporation (TSX: 
WEED, NYSE: CGC), is dedicated to educating healthcare practitioners, 
furthering the public's understanding of medical cannabis and its various 
applications, and cutting edge, commercialisable research and IP development. 
Founded in Canada, Spectrum Therapeutics operates in Australia, South America, 
Africa and across Europe. Its products are available in a wide range of 
potencies and formats designed to simplify the dialogue around strength and 
dosage by applying a colour-coded spectrum to categorise medical cannabis 
according to THC and CBD levels. 

Spectrum Therapeutics' offerings include whole flower cannabis, oils and new 
innovations such as Softgels in addition to single cannabinoid medicine 
Dronabinol under the brand Bionorica Ethics. Through product simplification, 
robust clinical research and ongoing education of healthcare professionals, 
Spectrum Therapeutics is committed to addressing the unmet medical needs of 
patients around the globe.

Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of 
the United States Private Securities Litigation Reform Act of 1995 and 
"forward-looking information" within the meaning of applicable Canadian 
securities legislation. Often, but not always, forward-looking statements and 
information can be identified by the use of words such as "plans", "expects" or 
"does not expect", "is expected", "estimates", "intends", "anticipates" or 
"does not anticipate", or "believes", or variations of such words and phrases 
or state that certain actions, events or results "may", "could", "would", 
"might" or "will" be taken, occur or be achieved. Forward-looking statements or 
information involve known and unknown risks, uncertainties and other factors 
which may cause the actual results, performance or achievements of Canopy 
Growth or its subsidiaries to be materially different from any future results, 
performance or achievements expressed or implied by the forward-looking 
statements or information contained in this news release. Examples of such 
statements include respect to project completion dates and grow projections. 
Risks, uncertainties and other factors involved with forward-looking 
information could cause actual events, results, performance, prospects and 
opportunities to differ materially from those expressed or implied by such 
forward-looking information, including content development and such risks 
contained in the Company's annual information form dated June 24, 2019 and 
filed with Canadian securities regulators available on the Company's issuer 
profile on SEDAR at www.sedar.com. Although the Company believes that the 
assumptions and factors used in preparing the forward-looking information or 
forward-looking statements in this news release are reasonable, undue reliance 
should not be placed on such information and no assurance can be given that 
such events will occur in the disclosed time frames or at all. The 
forward-looking information and forward-looking statements included in this 
news release are made as of the date of this news release and the Company does 
not undertake an obligation to publicly update such forward-looking information 
or forward-looking information to reflect new information, subsequent events or 
otherwise unless required by applicable securities laws.

Source - Spectrum Therapeutics